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Background: Depression has been associated with elevated white blood cell (WBC) count —
indicative of systemic inflammation — in cross-sectional studies, but no longitudinal study has
evaluated whether depressive symptoms predict subsequent WBC count or vice versa. We sought
to evaluate the bidirectional association between depressive symptoms and WBC count in
patients with coronary heart disease (CHD).
Methods: Depressive symptoms were assessed at baseline and annually during 5 consecutive
years of follow-up in 667 outpatients with stable CHD from the Heart and Soul Study. The presence
of significant depressive symptoms was defined as a score of 10 on the Patient Health
Questionnaire (PHQ-9) at one or more assessments. WBC count was measured in blood samples
collected at baseline and after 5 years of follow-up.
Results: Of the 667 participants, 443 (66%) had no depressive symptoms (PHQ-9 < 10), 86 (13%)
had depressive symptoms (PHQ-9  10) at 1 assessment, and 138 (21%) had depressive symptoms
at 2 or more annual assessments. Across the three groups, participants with recurrent depressive
symptoms had higher WBC levels after 5 years of follow-up ( p < .001). This relationship was
essentially unchanged after adjustment for demographics, traditional cardiovascular risk factors,
cardiac disease severity, inflammatory cytokine levels, and health behaviors ( p = .009). Baseline
WBC count was not associated with subsequent depressive symptoms ( p = .18).
Conclusions: Depressive symptoms independently predicted higher subsequent WBC count in
patients with stable CHD, but baseline WBC count did not predict subsequent depressive symptoms.
* Corresponding author at: University of California, San Francisco, 4150 Clement Street (111A1), San Francisco, CA 94121, United States.
Tel.: +1 415 750 2093; fax: +1 415 379 5573.
E-mail address: mary.whooley@ucsf.edu (M.A. Whooley).
Available online at www.sciencedirect.com
j our na l h omepa g e: www.e l se v ie r.c om/l oca te/ psyne ue n
0306-4530/$ — see front matter # 2012 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.psyneuen.2012.07.006
These findings support a unidirectional relationship in which depression is a risk-factor for
inflammation.
# 2012 Elsevier Ltd. All rights reserved.
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Depression (Aadahl et al., 2007) is common in patients with
cardiac disease, with prevalence rates nearly three times as
high as in the general population (Wells et al., 1993; Thombs
et al., 2006; Blumenthal, 2008). Depression has been found to
have a negative influence on cardiac prognosis (van Melle
et al., 2004), but the mechanisms of this association remain
unclear (de Jonge et al., 2010). Several studies have eval-
uated the association between depression and inflammatory
markers, including interleukin (IL)6, high sensitive C-reactive
protein (hsCRP), tumor necrosis factor (TNF)-a and its soluble
receptors (Penninx et al., 2003; Whooley et al., 2007; Kupper
et al., 2012; Vogelzangs et al., 2012). A meta-analysis
reported small to moderate cross-sectional associations
between depression and these cytokines, both in healthy
subjects and in cardiac patients (Howren et al., 2009). Cur-
rently, several prospective studies have been performed
(Gimeno et al., 2009; Stewart et al., 2009; Duivis et al.,
2011; Shaffer et al., 2011; Kupper et al., 2012). In a recent
study in heart failure patients, depressive symptoms at base-
line were associated with current and future inflammation
after 1 year follow-up, independent of classic cardiovascular
risk factors, disease severity and adverse health behaviors
(Kupper et al., 2012). In line with this, we found in a previous
study that depressive symptoms predicted subsequent levels
of hsCRP and IL-6 over a period of 5 years in patients with
coronary heart disease (CHD), but not vice versa (Duivis et al.,
2011). However, the association of depressive symptoms with
subsequent inflammation in this study was mainly explained by
the presence of adverse health behaviors (Duivis et al., 2011).
A relatively understudied inflammatory marker in the
depression—inflammation relationship is white blood cell
(WBC) count. Like cytokines, WBCs (or leukocytes) are part
of the immune system, but they come from different sources.
WBCs are formed in the bone marrow from hematopoietic
stem cells, whereas cytokines are protein messengers pro-
duced by mature immune cells, e.g. monocytes (Widmaier
et al., 2011). Although WBCs and cytokines have different
physiological roles in the immune response, they interact in a
complex way. Thus, it is unclear whether depression
increases the production of WBC in the bone marrow, or
increases the secretion of inflammatory cytokines from
mature WBC in peripheral vessels, or both.
Earlier research has shown that higher WBC count is
associated with increased risk of atherosclerosis (Halvorsen
et al., 2009; Sekitani et al., 2010) and cardiac mortality
(Weijenberg et al., 1996; Dragu et al., 2008). Furthermore,
decreased lymphocyte percentage is associated acute cor-
onary syndrome and major adverse cardiac events in CHD
patients (Bian et al., 2010), whereas higher monocyte and
neutrophil count are associated with a history of cardiovas-
cular disease (Pinto et al., 2004). Moreover, several studies
have reported a cross-sectional association between high
WBC count and depression (Surtees et al., 2003; Panagiotakos
et al., 2004; Kop et al., 2010) in participants free of cardiacdisease. In contrast, depressive symptoms have also been
associated with lower levels of WBC count in elderly patients
in the setting of acute hospital admission (German et al.,
2006). Whether depressive symptoms are associated with
WBCs, and if so, whether depressive symptoms predict higher
WBC levels or vice versa, has not been evaluated in patients
with cardiovascular disease. We therefore sought to investi-
gate the temporal, bidirectional associations between
depressive symptoms and WBC count, while adjusting for
socio-demographic factors, traditional risk factors, cardiac
disease severity, and inflammatory cytokines.
2. Methods and materials
2.1. Design and participants
The Heart and Soul Study is an ongoing prospective cohort
study of psychosocial factors and health outcomes in patients
with coronary heart disease (CHD). Methods have been
described previously (Whooley et al., 2008). Briefly, 1024
outpatients with stable CHD were recruited and completed a
baseline examination between September 2000 and Decem-
ber 2002. Following the baseline examination, patients
received annual telephone calls for assessment of depressive
symptoms. Between September 2005 and December 2007,
667 participants (80% of the 829 survivors) completed a 5-
year follow-up examination that included measures of
inflammation. The study protocol was approved by the appro-
priate institutional review boards, and the study was per-
formed in accordance with the standards of the most recent
Helsinki declaration (2008). All participants provided written
informed consent.
2.2. Depressive symptoms
Depressive symptoms were assessed at baseline and annually
during 5 consecutive years using the 9-item Patient Health
Questionnaire (PHQ-9), a self-report instrument that mea-
sures the frequency of depressive symptoms corresponding to
the 9 Diagnostic and Statistical Manual-IV criteria for depres-
sion (Spitzer et al., 1999). A paper and pencil version of the
PHQ was administered at the baseline examination (year 0),
telephone versions were administered annually (after 1, 2, 3
and 4 years of follow-up), and a paper and pencil version was
again administered after the 5th year of follow-up (year 5).
Of the 667 participants who completed the 5-year examina-
tion, 640 (96%) completed 5 or more interviews, 23 (3.4%)
completed 4 interviews, 3 (0.4%) completed 3 interviews,
and 1 (0.1%) completed 2 interviews.
At each assessment, participants were asked to indicate
the frequency of experiencing each depressive symptom
during the last two weeks. Every one of the 9 symptoms
was scored as not at all (0), several days (1), more than half
the days (2), or nearly every day (3), with a total score range
of 0—27 (Kroenke et al., 2001). The PHQ-9 has demonstrated
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interview for depression in patients with CHD (Stafford
et al., 2007; Thombs et al., 2008). Telephone and in-person
PHQ assessments yield similar results (Pinto-Meza et al.,
2005). As a summary measure of mean depressive symptoms
over time, we calculated the sum of the annual PHQ scores
divided by the number of interviews completed. We also
created a 3-category variable indicating significant depres-
sive symptoms at (1) 2 or more interviews (N = 138), (2) at
one interview (N = 86), or (3) at no interview (N = 443), where
significant depressive symptoms were defined as PHQ  10.
We chose these groups for analysis because further divisions
would have yielded too few participants in each category.
2.3. White blood cell count
Fasting blood samples were obtained at baseline and after 5
years of follow-up to determine WBC count. Prior to each
study appointment, participants completed an overnight fast
except for taking their regularly prescribed medications. A
21G butterfly needle was inserted intravenously in the fore-
arm, and blood samples were drawn into EDTA tubes. WBC
was measured using a Beckman Coulter analyzer (Beckman
Coulter, Inc., California). Laboratory technicians were
blinded to the depression status of the participants.
2.4. Cytokines
Cytokines, amongst others, are activated by WBCs (Gidron
et al., 2002). In order to determine if depressive symptoms
are associated with WBC count independent of cytokines,
analyses were adjusted for IL-6 and hsCRP. Clotting factors
also have both pro-inflammatory and atherogenic properties.
We adjusted for fibrinogen to rule out the possibility that
WBC levels were higher due to greater thrombogenesis. High
sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)
and fibrinogen were determined from plasma and serum
samples at baseline and after 5 years of follow-up. Labora-
tory technicians were blinded to the depression status of the
participants.
High-sensitivity C-reactive protein (hsCRP) levels were
measured using the Roche Integra assay or the Beckman
Extended Range assay. Interassay coefficients of variation
were 1.66—5.32%. IL-6 was determined using the Millipore
Milliplex Map kit, with interassay coefficients of variation
from 6.3 to 11.6%. Concentrations of serum fibrinogen were
determined by the Clauss assay with coefficients of
variation <3%. The individual inflammatory markers showed
small, but significant correlations with WBC at baseline
(log hsCRP: r = .28, p < .0001; IL-6: r = .26, p < .0001; fibri-
nogen: r = .26, p < .0001) and at the year 5 assessment
(log hsCRP: r = .26, p < .0001; IL-6: r = .25, p < .0001; fibri-
nogen: r = .26, p < .0001).
2.5. Cardiac disease severity
The presence of congestive heart failure (CHF) and myocar-
dial infarction (MI) were determined by self-report at base-
line. Year 5 CHF and MI were determined by reviewing
medical records. CHF was defined as hospitalization for a
clinical syndrome involving at least 2 of the following:paroxysmal nocturnal dyspnea, orthopnea, elevated jugular
venous pressure, pulmonary rates, third heart sound, and
cardiomegaly or pulmonary edema on chest radiography.
These signs and symptoms must have represented a clear
change from the usual clinical status (Ren et al., 2007). MI
was defined using standard criteria (Luepker et al., 2003).
High-density lipoprotein levels were measured from fasting
venous blood samples, and non-HDL cholesterol was calcu-
lated as total minus HDL cholesterol. To assess cardiac func-
tion, left ventricular ejection fraction was measured using 2-
dimensional echocardiography. To assess exercise capacity,
participants underwent a symptom-limited, graded exercise
treadmill test based on a standard Bruce protocol with
continuous 12-lead ECG monitoring. Participants were asked
to exercise until they experienced dyspnea, symptom-lim-
ited fatigue, chest discomfort or ECG changes suggestive of
ischemia (Gibbons et al., 2002) Exercise capacity was calcu-
lated as the total number of metabolic equivalents
(1 MET = 3.5 mL of oxygen uptake/kg/min) achieved at peak
exercise.
2.6. Health behaviors
At baseline and at the 5-year examination, smoking status
was determined by self-report. Participants were asked to
rate their level of physical activity by answering the following
question: ‘‘Which of the following statements best describes
how physically active you have been during the last month,
that is, done activities such as 15—20 minutes of brisk walk-
ing, swimming, general conditioning, or recreational
sports?’’ Self-report of physical activity has been shown to
be a valid, accurate and reliable (Ainsworth et al., 1993;
Bowles et al., 2004; Aadahl et al., 2007; Kurtze et al., 2008).
Physical inactivity was defined as not at all or a little active
vs. fairly, quite, very or extremely active. Height and weight
were measured, and used to calculate body mass index (BMI:
weight in kilograms divided by the square of height in
meters). Waist and hip circumference were measured to
calculate waist—hip ratio. The correlation between BMI
and waist and hip circumference was low (baseline:
r = .35, p < .0001; year 5: r = .34, p < .0001). Alcohol con-
sumption was assessed with the Audit-C self-report ques-
tionnaire (Bush et al., 1998).
2.7. Other patient characteristics
Age, gender, ethnicity, education, and medical history were
determined by self-report both at baseline and at the 5-year
examination. Participants were asked to bring all their med-
ication bottles to the study appointment, and all current
medications were recorded. Medications were categorized
using Epocrates Rx (San Mateo, California) and were defined
as a dichotomous variable (yes or no). Cognitive function was
measured using the Short Portable Mental Status Question-
naire (Pfeiffer, 1975). To evaluate the possibility that sleep
disturbance may be on the pathway between depression and
WBC, we assessed sleep quality using a single item from the
Pittsburgh Sleep Quality Index (Buysse et al., 1989) Partici-
pants were asked how they would rate their overall sleep
quality during the last month (excellent, very good, good,
fair, poor).
482 H.E. Duivis et al.2.8. Statistical analyses
We compared characteristics of participants across the
three depression subgroups using ANOVA for continuous
variables and chi-square tests for dichotomous variables.
General Linear Models were used to compare mean levels
of WBC at baseline and at 5-year follow-up across the
three subgroups of participants. We used standardized bs
to determine the magnitude of the associations between
depressive symptoms (entered as both a continuous and
categorical variable) and WBC count. To further evaluate
the association between depressive symptoms and WBC
count, we used multivariate analysis of variance and
created four models which additionally adjusted forTable 1 Characteristics of 667 participants with coronary heart
previous 5 years.
Variable No depressive
symptoms (N = 443)
N or mean % or SD
Demographic characteristics
Age (years) 72.8 9.2 
Male (%) 381 86% 
White (%) 277 63% 
High school graduate (%) 402 91% 
Comorbid conditions
Hypertension (%) 324 74% 
Myocardial infarction (%) 205 47% 
Congestive heart failure (%) 68 16% 
Diabetes mellitus (%) 122 28% 
Cardiac disease severity and risk factors
Left ventricular ejection fraction 0.62 0.11
Exercise capacity (METS) 6.98 2.98
LDL cholesterol (mg/dl) 93.7 34.2 
HDL cholesterol (mg/dl) 47.5 14.8 
Non-HDL cholesterol 115.7 38.9 
Hemoglobin (g/DL) 14.03 1.54
Medication use
Aspirin (%) 338 76% 
Beta blocker (%) 300 68% 
Renin—angiotensin system inhibitor(%) 298 67% 
Statin (%) 123 28% 
Corticosteroids (%) 14 3% 
Non-steroidal anti-inflammatory drugs(%) 58 13% 
Cytokine levels
Log high sensitive C-reactive protein 0.34 1.14
Log Interleukin-6 1.19 0.66
Fibrinogen 371.26 78.65
Health behaviors
Regular alcohol use (%) 132 30% 
Body mass index (kg/m2) 28.13 5.03
Current smoking (%) 42 10% 
Physically inactive (%) 140 32% 
Waist—hip ratio 0.97 0.09
LDL: low-density lipoprotein; HDL: high-density lipoprotein; METS: me(model 1) other patient characteristics associated with
depressive symptoms, i.e. age, gender, education, race,
aspirin and corticosteroid use, history of diabetes, MI,
CHF, and exercise capacity, (model 2) model 1 + log hsCRP,
log IL-6, and fibrinogen, (model 3) model 2 + BMI and
waist—hip ratio, and (model 4) model 3 + physical activity
and smoking. BMI and waist—hip ratio were analyzed in a
separate model to investigate the effects of overweight
or abdominal fat separately from physical activity and
smoking. For analyses of baseline WBC levels, we adjusted
for characteristics measured at the baseline exam. For
analyses of 5-year WBC levels, we adjusted for character-
istics measured at the 5-year exam. Analyses were per-





at 2 or more
interviews (N = 138)
p
 N or mean % or SD N or mean % or SD
68.6 12.0 66.3 11.0 <0.001
62 72% 106 77% 0.001
42 49% 79 57% 0.05
70 81% 112 81% 0.001
65 77% 110 80% 0.28
53 63% 70 51% 0.02
17 20% 42 31% <0.001
35 41% 35 26% 0.03
 0.63 0.11 0.60 0.13 0.24
 6.22 3.01 6.32 3.15 0.03
98.0 28.6 95.0 32.9 0.54
47.3 18.6 45.6 14.3 0.47
124.0 34.1 120.8 37.0 0.10
 13.46 1.72 13.89 1.81 0.01
58 67% 86 62% 0.003
62 72% 91 66% 0.62
55 64% 85 62% 0.44
20 23% 26 19% 0.10
6 7% 6 4% 0.24
11 13% 23 17% 0.54
 0.58 1.30 0.7 1.30 0.006
 1.19 0.71 1.38 0.71 0.01
 370.25 86.62 390.66 101.98 0.06
19 23% 32 24% 0.20
 29.76 6.01 29.6 6.97 0.004
13 16% 37 27% <0.001
41 49% 82 60% <0.001
 0.97 0.09 0.98 0.07 0.60
tabolic equivalents (1 MET = 3.5 mL of oxygen uptake/kg/min).
Table 2 Mean  SE white blood cell count at 5-year follow-up examination, by the presence of depressive symptoms during
previous 5 years.









at 2 or more interviews
N = 138
p
Mean SD/SEa Mean SD/SEa Mean SD/SEa
Unadjusted 6.49 1.91 6.54 2.04 7.32 2.49 <0.001
Model 1 6.71 0.20 6.69 0.24 7.34 0.23 0.001
Model 2 6.60 0.20 6.57 0.24 7.20 0.22 0.002
Model 3 6.61 0.21 6.57 0.25 7.14 0.23 0.007
Model 4 6.69 0.23 6.64 0.26 7.21 0.25 0.009
Model 1: adjusted for year 5 age, gender, education, race, history of diabetes, myocardial infarction, heart failure, use of aspirin,
corticosteroids, exercise capacity, and baseline white blood cell count. Model 2: adjusted for model 1 variables + year 5 log high sensitive C-
reactive protein, log interleukin 6, and fibrinogen. Model 3: adjusted for model 2 variables + year 5 body mass index and waist to hip ratio.
Model 4: adjusted for model 3 variables + year 5 physical inactivity and smoking.
a Unadjusted values use standard deviation, adjusted values use standard error.
Table 3 Summary Patient Health Questionnaire 9 score
(average score from 6 annual assessments) as a predictor
of white blood cell count at follow up exam.
Standardized b p value
Unadjusted 0.168 <0.001
Model 1 0.106 0.002
Model 2 0.107 0.001
Model 3 0.098 0.003
Model 4 0.094 0.007
Model 1: adjusted for 5-year age, gender, education, race, history
of diabetes, myocardial infarction, heart failure, use of aspirin,
corticosteroids, exercise capacity, and baseline white blood cell
count. Model 2: adjusted for model 1 variables + year 5 log high
sensitive C-reactive protein, log interleukin 6, and fibrinogen.
Model 3: adjusted for model 2 variables + year 5 body mass index
and waist—hip ratio. Model 4: adjusted for model 3 variables + -
year 5 physical activity and smoking.
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3.1. Characteristics of participants
Of the 667 participants with stable coronary heart disease
who completed both the baseline and 5-year examinations,
443 (66%) reported no significant depressive symptoms (PHQ-
9 score  10) at any of the annual interviews, 86 (13%) had
depressive symptoms at one interview only, and 138 partici-
pants (21%) had depressive symptoms at 2 or more annual
interviews. As compared with the 162 participants who were
alive after 5-years of follow-up but did not complete the
follow-up examination, the 667 participants who completed
the exam were older (mean age 66  10 vs. 64  12; p = .04)
and had lower baseline depressive symptom scores (mean
PHQ-9 scores 4.75  5.26 vs. 6.77  5.84; p < .001) as well as
lower baseline WBC count (6.36  1.76 vs. 6.95  2.21;
p < .001).
Baseline patient characteristics stratified by depression
are presented in Table 1. As compared to participants without
depressive symptoms, those with depressive symptoms were
younger and less likely to be male, white, or high school
educated. They were more likely to have a history of dia-
betes, MI, and CHF. They had worse exercise capacity and
higher BMI. Greater depressive symptoms were associated
with lower hemoglobin (Hb) levels. Participants with signifi-
cant depressive symptoms were less likely to use aspirin and
more likely to smoke and to be physically inactive. The 3
groups had similar levels of hypertension, left ventricular
ejection fraction, cholesterol levels, use of cardio-protective
medications, and waist—hip ratio.
3.2. Depressive symptoms as a predictor of
white blood cell count
Patients who reported significant recurrent depressive symp-
toms at 2 or more interviews had higher WBC count levels at
5-year follow-up ( p < .001) than patients who were not
depressed or reported depressive symptoms at 1 interviewonly. Recurrent depressive symptoms remained significantly
associated with 5-year levels of WBC count after adjustment
for age, gender, education, race, history of diabetes, MI, CHF,
cardiac disease severity, aspirin use, and baseline WBC count
( p = .001) (Table 2). Adjustment for cytokine levels (hsCRP,
IL-6 and fibrinogen) attenuated but did not eliminate this
association ( p = .002) (Table 2). Even after adjusting for
health behaviors (BMI, waist to hip ratio, physical activity,
and smoking), significant depressive symptoms remained
associated with higher WBC count ( p = .009) (Table 2). The
association also persisted after further adjustment for cog-
nitive function ( p = .02). When we analyzed both depressive
symptoms and WBC as continuous variables, the average of
PHQ scores across the annual assessments predicted subse-
quent levels of WBC count in both unadjusted and fully
adjusted models (Table 3).
We next evaluated sleep quality as a potential mediator
between depressive symptoms and WBC. Poor sleep quality
was reported by 18% of patients with no depressive symp-
toms, 46% of patients with depressive symptoms at one
Table 4 Mean  SE baseline white blood cell count at baseline, by subsequent depressive symptoms.









at 2 or more interviews
N = 138
p
Mean SD/SEa Mean SD/SEa Mean SD/SEa
Unadjusted 6.28 1.66 6.40 2.03 6.60 1.90 0.18
Model 1 6.53 0.29 6.44 0.31 6.59 0.32 0.83
Model 2 6.32 0.28 6.27 0.30 6.45 0.31 0.72
Model 3 6.32 0.29 6.27 0.31 6.41 0.32 0.81
Model 4 6.70 0.30 6.64 0.32 6.63 0.32 0.91
Model 1: adjusted for baseline age, gender, education, race, history of diabetes, myocardial infarction, heart failure, use of aspirin,
corticosteroids, and exercise capacity. Model 2: adjusted for model 1 variables + baseline log high sensitive C-reactive protein, log
interleukin 6, and fibrinogen. Model 3: adjusted for model 2 variables + baseline body mass index and waist—hip ratio. Model 4: adjusted for
model 3 variables + baseline physical activity and smoking.
a Unadjusted values use standard deviation, adjusted values use standard error.
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or more interviews ( p < .001). After adjustment for sleep
quality in addition to all the above variables, the association
between average depressive symptoms score and WBC was no
longer present ( p = .34).
3.3. White blood cell count as a predictor of
subsequent depressive symptoms
We found no evidence that baseline WBC was associated with
subsequent depressive symptoms. Baseline WBC count was
not significantly different in participants who reported sig-
nificant depressive symptoms at 2 or more interviews com-
pared to participants without significant depressive
symptoms or those who reported significant depressive symp-
toms at 1 interview only (Table 4).
4. Discussion
The current study showed that participants with recurrent
depressive symptoms had higher WBC levels after 5 years of
follow-up than those without or only a single episode of
depressive symptoms. These findings persisted after adjust-
ment for demographic characteristics, baseline WBC count,
cardiac disease severity, medication use, and health beha-
viors. However, depressive symptoms were not associated
with WBC after further adjustment for sleep quality. These
findings suggest that depressive symptoms are predictive of
inflammation in patients with coronary heart disease and
raise the possibility that poor sleep quality may mediate this
association.
The potential mechanisms by which depressive symptoms
lead to elevations in WBC are unclear. In our previous study,
we found that poor health behaviors explained the major part
of the prospective relation between depressive symptoms
and subsequent elevated levels of inflammatory cytokines
(Duivis et al., 2011). In contrast, the present study demon-
strated that depressive symptoms remained strongly predic-
tive of WBC even after adjustment for hsCRP, IL-6, fibrinogen,body mass index, waist—hip ratio, physical activity and
smoking. One possible explanation is that elevated WBC is
a reflection of chronic stress, which may stimulate hemato-
poietic stem cells in the bone marrow to produce WBCs
(Widmaier et al., 2011). In this cascade, the role of health
behaviors might be less important than in the more down-
stream depression—cytokine relationship. Another possible
explanation is that depression may cause sleep disturbance,
and poor sleep quality may lead to elevations in WBC. Inter-
estingly, we found that the link between depressive symp-
toms and WBC was no longer present after adjustment for
sleep quality. These findings suggest that poor sleep quality
may be on the pathway between depressive symptoms and
elevated WBC. A third potential explanation could be that
patients with chronic depression or stress may have hyper-
cortisolemia or reduced vagal activity, both which may lead
to higher inflammation, possibly manifested by increased
WBC (Gidron et al., 2007).
We found that the group of participants reporting depres-
sive symptoms at two or more interviews had the highest
levels of WBC count. Two retrospective studies conducted by
Liukkonen and colleagues, and by Hamer and colleagues
respectively reported that patients with recurrent depres-
sive symptoms had higher levels of inflammation (Liukkonen
et al., 2006; Hamer et al., 2009) whereas Matthews et al.
(2010) showed that in a group of middle-aged women, those
who experienced recurrent depressive symptoms had greater
progression of coronary artery calcification. Taken together,
these findings suggest that recurrent or chronic depressive
symptoms may be more strongly associated with inflamma-
tion (and adverse health outcomes) than a single episode of
depressive symptoms.
The results of this study could be an important step in
better understanding the underlying physiological mechan-
isms of the adverse cardiac effects of depression. Previous
studies have shown that WBC is a predictor of new cardiac
events or even cardiac death (Pinto et al., 2004). As reported
in this study, WBC count is higher in patients with cardiac
disease reporting recurrent significant depressive symptoms.
It could be hypothesized that depression might contribute to
Depression and white blood cell count in cardiac disease 485new cardiac events through a higher WBC count. However, it
should be kept in mind that more factors could play a role in
the relationship between depression and CHD. For instance,
Kop et al. (2010) found in a healthy sample that autonomic
nervous system (ANS) dysfunction and elevated levels of
inflammatory cytokines explained a small proportion of the
mortality risk associated with depression. We have also found
(Whooley et al., 2008) that inflammatory cytokines explain a
small part of the association between depressive symptoms
and adverse cardiovascular events, but most of this associa-
tion is explained by poor health behaviors. Future research is
needed to provide more insight on the mechanisms under-
lying the depression—CHD relationship. Repeated assess-
ments of depression, as well as simultaneous assessment
of multiple physiological mechanisms and health behaviors,
could help better define the joint pathophysiology.
The results of the current study should also be viewed in
light of several limitations. The present study determined
the complete WBC count, but not the five different white
blood cell types included in the complete count (Widmaier
et al., 2011). Thus, we are unable to determine what cell
type is responsible for this association. One possibility is that
monocytes activate, or differentiate into macrophages that
activate, cytokine production (Widmaier et al., 2011). Psy-
chological factors, such as emotional support and perceived
control have been associated with percent monocytes in
acute coronary syndrome patients (Gidron et al., 2003).
Furthermore, monocytes have been associated with ather-
ogenesis (Ley et al., 2011) and with a history of cardiac
disease (Pinto et al., 2004). Differentiating between these
cells could possibly provide more insight into the relation-
ship between depression, inflammation and cardiac disease.
In addition, WBC count was only determined at baseline and
at the year 5 follow-up. Furthermore, this study focuses on
outpatients with stable coronary heart disease. Our results
may therefore not apply to healthy participants or to
patients with acute coronary syndromes. Also, the study
population mostly consists of older men, so therefore the
results may not be generalizable to either women or younger
men. Finally, 20% (162/829) of surviving participants did not
complete the 5-year follow up examination. These partici-
pants had worse depression scores than those who com-
pleted the examination, so including them would probably
have strengthened the association between depression and
WBC levels.
In conclusion, we found that recurrent depressive
symptoms were prospectively associated with subsequent
levels of WBC count, independent of inflammatory cyto-
kine levels and health behaviors or baseline WBC. These
findings raise the possibility that WBC count is a potential
mediator in the relationship between depression and
adverse cardiac outcomes.
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